Tolley K - Search Results

1

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.

Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q. Tolley K, et al. J Med Econ. 2010;13(3):559-70. doi: 10.3111/13696998.2010.516203. J Med Econ. 2010. PMID: 20812793 Free article.

2

Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom.

Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R. Karnon J, et al. Among authors: tolley k. Curr Med Res Opin. 2008 Jun;24(6):1609-21. doi: 10.1185/03007990802077442. Epub 2008 Apr 24. Curr Med Res Opin. 2008. PMID: 18439348

3

A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.

Tolley K, Kemmett D, Thybo S, Nasr R, Smethurst H. Tolley K, et al. Eur J Health Econ. 2016 Apr;17(3):287-304. doi: 10.1007/s10198-015-0679-8. Epub 2015 Mar 21. Eur J Health Econ. 2016. PMID: 25795391

4

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. Charokopou M, et al. Among authors: tolley k. BMC Health Serv Res. 2015 Nov 5;15:496. doi: 10.1186/s12913-015-1139-y. BMC Health Serv Res. 2015. PMID: 26541516 Free PMC article.

5

The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. Charokopou M, et al. Among authors: tolley k. Diabet Med. 2015 Jul;32(7):890-8. doi: 10.1111/dme.12772. Epub 2015 Apr 30. Diabet Med. 2015. PMID: 25817050 Clinical Trial.

6

Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.

Karnon J, Tolley K, Vieira J, Chandiwana D. Karnon J, et al. Among authors: tolley k. Clin Drug Investig. 2012 Dec;32(12):805-15. doi: 10.1007/s40261-012-0008-2. Clin Drug Investig. 2012. PMID: 23026844

7

Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.

Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Tolley K, et al. Eur J Health Econ. 2013 Oct;14(5):749-59. doi: 10.1007/s10198-012-0419-2. Epub 2012 Sep 1. Eur J Health Econ. 2013. PMID: 22941034

8

Cost analysis of autologous blood transfusion, using cell salvage, compared with allogeneic blood transfusion.

Duffy G, Tolley K. Duffy G, et al. Among authors: tolley k. Transfus Med. 1997 Sep;7(3):189-96. doi: 10.1046/j.1365-3148.1997.d01-25.x. Transfus Med. 1997. PMID: 9316218

9

Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.

Proudfoot C, Gautam R, Cristino J, Agrawal R, Thakur L, Tolley K. Proudfoot C, et al. Among authors: tolley k. Eur J Health Econ. 2023 Apr;24(3):453-467. doi: 10.1007/s10198-022-01485-3. Epub 2022 Jul 5. Eur J Health Econ. 2023. PMID: 35790595 Free PMC article.

10

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

Gros B, Galán A, González-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I. Gros B, et al. Among authors: tolley k. Health Econ Rev. 2015 Dec;5(1):49. doi: 10.1186/s13561-015-0049-3. Epub 2015 Jun 11. Health Econ Rev. 2015. PMID: 26062537 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

157 results

Search Page

Filters